文献速递乳腺癌

早期乳腺癌肿瘤PIK3CA基因型与预后:个体患者数据汇总分析

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
PubMed 文献 · J Clin Oncol · 2018-02-22

该汇总分析纳入19项研究10319例早期乳腺癌患者,评估PIK3CA突变与预后的关联。PIK3CA突变率32%,与ER阳性、高龄、低分级和较小肿瘤相关。

要点

  • PIK3CA突变率32%,在ER阳性/HER2阴性亚型中最高(37%)。
  • 单因素分析PIK3CA突变与更好IDFS相关(HR 0.77),5年内效应更强。

核心结论

  • 在大型汇总分析中,PIK3CA突变与更好的IDFS、DDFS和OS显著相关,但校正其他预后因素后预后效应减弱。

研究设计与样本

  • 研究为个体患者数据汇总分析,纳入19项研究共10319例早期乳腺癌患者,中位OS随访6.9年。
  • 采用Cox回归模型校正年龄、肿瘤大小、淋巴结、分级、ER状态、HER2状态、治疗和研究。

主要发现

  • PIK3CA突变在ER阴性/HER2阴性、HER2阳性和ER阳性/HER2阴性亚型中的发生率分别为18%、22%和37%。

临床怎么用

  • PIK3CA突变状态可作为早期乳腺癌预后评估的参考指标,尤其在ER阳性/HER2阴性亚型中突变率较高。
  • PIK3CA突变的预后价值随时间变化,5年内保护效应更强,长期需结合其他因素综合判断。

局限性

  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall survival (OS) were also assessed, overall and by breast cancer subtypes. Results Data from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787 patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%) received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations occurred in 32% of patients, with significant associations with ER positivity, increasing age, lower grade, and smaller size (all P < .001). Prevalence of PIK3CA mutations was 18%, 22%, and 37% in the ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84; P < .001), with evidence for a stronger effect in the first years of follow-up (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P < .001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); > 10 years: (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA genotype remained significant for improved IDFS ( P = .043), but not for the DDFS and OS end points. Conclusion In this large pooled analysis, PIK3CA mutations were significantly associated with a better IDFS, DDFS, and OS, but had a lesser prognostic effect after adjustment for other prognostic factors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zardavas D, Te Marvelde L, Milne RL, et al. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. J Clin Oncol. 2018. PMID: 29470143. doi:10.1200/JCO.2017.74.8301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。